Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism of Retigabine (D-23129), a Novel Anticonvulsant

Roland Hempel, Hubert Schupke, Patrick J. McNeilly, Kristina Heinecke, Christiane Kronbach, Christian Grunwald, Gottfried Zimmermann, Christian Griesinger, Jürgen Engel and Thomas Kronbach
Drug Metabolism and Disposition May 1999, 27 (5) 613-622;
Roland Hempel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hubert Schupke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick J. McNeilly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristina Heinecke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Kronbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Grunwald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gottfried Zimmermann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Griesinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Engel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Kronbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Retigabine (D-23129,N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester) is a potent anticonvulsant in a variety of animal models. Rats metabolized [14C]retigabine mainly through glucuronidation and acetylation reactions. Glucuronides were detected in incubates with liver microsomes or slices, in plasma, and in bile and feces but were absent in urine (0–24 h) that contained about 2% of the dose as retigabine and approximately 29% of the dose in > 20 metabolites, which are derived mainly from acetylation reactions. About 67% of the radioactivity was excreted into feces, approximately 10% of the dose as glucuronide. The metabolite pattern in the urine (0–24 h) of dogs was comparatively simple in that retigabine (13%), retigabine-N-glucuronide (5%), and retigabine-N-glucoside (1%) were present. In the same 24-h interval, about 39% of unchanged retigabine was excreted into feces. Plasma profiling and spectroscopic analysis (liquid chromatography with tandem mass spectrometry NMR) of two isolated urinary metabolites obtained after single oral dosing of 600 mg retigabine in healthy volunteers indicated that both acetylation and glucuronidation are major metabolic pathways of retigabine in humans. We found that in vitro assays with liver slices from rat and humans reveal the major circulating metabolites in vivo.

Footnotes

  • Send reprint requests to: Dr. Roland Hempel, Corporate Research & Development, ASTA Medical Group, Biochemistry Dresden, Arzneimittelwerk Dresden GmbH, Meissner Str. 191, D-01445 Radebeul, Germany. E-mail:Dr-Roland.Hempel{at}astamedica.de

  • This work was supported by the Sächsisches Ministerium für Arbeit und Wirtschaft (project number 1791).

  • 1 Introduced on the market by ASTA Medica AG, Frankfurt/Main, Germany; trade name: Katadolon.

  • Abbreviations used are::
    CID
    collision induced dissociation
    DMSO
    dimethyl sulfoxide
    HPLC
    high-performance liquid chromatography
    MS
    mass spectroscopy
    LC
    liquid chromatography
    UDPGA
    uridine 5′-diphosphoglucuronic acid
    SPE
    solid phase extraction
    SPHPLC
    semipreparative chromatography
    A/D
    adsorption/desorption
    ESI-MS
    electrospray mass spectroscopy
    TSP-MS
    thermospray mass spectroscopy
    NMR
    nuclear magnetic resonance
    • Received July 22, 1998.
    • Accepted January 26, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (5)
Drug Metabolism and Disposition
Vol. 27, Issue 5
1 May 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism of Retigabine (D-23129), a Novel Anticonvulsant
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolism of Retigabine (D-23129), a Novel Anticonvulsant

Roland Hempel, Hubert Schupke, Patrick J. McNeilly, Kristina Heinecke, Christiane Kronbach, Christian Grunwald, Gottfried Zimmermann, Christian Griesinger, Jürgen Engel and Thomas Kronbach
Drug Metabolism and Disposition May 1, 1999, 27 (5) 613-622;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Metabolism of Retigabine (D-23129), a Novel Anticonvulsant

Roland Hempel, Hubert Schupke, Patrick J. McNeilly, Kristina Heinecke, Christiane Kronbach, Christian Grunwald, Gottfried Zimmermann, Christian Griesinger, Jürgen Engel and Thomas Kronbach
Drug Metabolism and Disposition May 1, 1999, 27 (5) 613-622;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Humanized PXR-CAR-CYP3A4/7 Mouse as Model of Induction
  • Ozanimod Human Metabolism and Disposition
  • High-Throughput Characterization of SLCO1B1 VUS
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics